Evidence boundary: This is an evidence-design comparison of distinct investigated or approved molecules. It is not a product comparison, purchasing recommendation, or assertion that any research material reproduces a clinical formulation.
Retatrutide, tirzepatide, and semaglutide represent three stages in the development of incretin-based metabolic research: single-, dual-, and triple-receptor strategies. Comparing them is scientifically useful because it shows how the field is attempting to build on earlier approaches.
| Compound | Principal receptor design |
|---|---|
| Semaglutide | GLP-1 receptor agonist |
| Tirzepatide | GIP/GLP-1 dual agonist |
| Retatrutide | GIP/GLP-1/glucagon triple agonist |
Retatrutide’s highest reported mean weight reductions appear numerically larger than results reported in many semaglutide and tirzepatide trials. That makes the triple-agonist approach an especially compelling research direction. Whether the molecule is truly superior can only be answered fairly through direct comparison.
Why separate trials cannot establish a winner
Trials may differ in:
- Diabetes status and baseline body weight
- Inclusion and exclusion criteria
- Treatment duration
- Dose-escalation strategy
- Discontinuation rates
- Rescue treatment
- Missing-data assumptions
- Efficacy, treatment-regimen, or treatment-policy estimands
Even small differences can shift the reported mean. A larger percentage in one trial does not isolate the drug as the reason.
What direct evidence existed?
The studies needed to answer that question were already underway. TRIUMPH-5 was directly comparing retatrutide with tirzepatide in obesity, and another study was comparing retatrutide with semaglutide in type 2 diabetes.
Without those results, the evidence could not establish comparative weight loss, glycemic effects, discontinuation, gastrointestinal tolerability, heart-rate effects, serious adverse events, or participant preference.
Safety comparisons are even harder
Semaglutide and tirzepatide had larger and more mature safety databases, regulatory reviews, and real-world exposure. Retatrutide had a smaller, shorter, sponsor-concentrated public safety record with incomplete Phase 3 disclosure.
It is therefore unsupported to claim that retatrutide has fewer side effects. A newer drug can appear to have fewer rare events simply because fewer people have been followed for less time.
What can reasonably be said?
Trials of LY3437943 have reported numerically competitive body-weight findings, and its triple-receptor design is scientifically distinct. Whether those differences persist in direct comparison requires the randomized head-to-head results and complete safety reporting.
Bottom line
LY3437943 is not simply a stronger version of semaglutide or tirzepatide. It is a distinct investigated molecule testing whether glucagon-receptor activity can extend the achievements of single- and dual-agonist research. Its reported numerical results make that hypothesis scientifically interesting; head-to-head trials will determine whether an advantage appears under direct comparison.